AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

COLL · NASDAQ · Drug Manufacturers - Specialty & Generic

Collegium Pharmaceutical (COLL)

Commercializes ADHD and pain-management medicines across a U.S. prescription portfolio.

$22.78

After hours−0.02 (−0.09%)

At close$22.80(−1.04%)

In millions of USD, except per-share figures

In millions	Q3 FY23Sep 2023	Q4 FY23Dec 2023	Q1 FY24Mar 2024	Q2 FY24Jun 2024	Q3 FY24Sep 2024	Q4 FY24Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25Dec 2025	Q1 FY26Mar 2026	Q2 FY26Jun 2026
Revenue	137	150	145	145	159	182	178	188	209	205	194	200
Cost of revenue	56	55	53	54	63	84	80	80	80	77	76	90
Gross profit	80	95	91	91	97	98	97	108	129	128	117	110
	35	33	42	43	62	60	76	73	66	69	85	107
	35	33	42	43	62	63	76	74	66	68	0	107
Selling & marketing	0	7	0	0	0	0	0	0	0	0	0	0
General & administrative	0	26	0	0	0	0	0	0	0	0	0	107
Other expenses	0	0	0	0	0	−3	−1	0	0	2	85	0
Operating income	45	62	49	47	35	38	22	35	64	59	32	4
	−16	−15	−13	−18	−19	−21	−19	−18	−20	−30	−13	−17
Interest income	5	4	4	4	3	2	2	2	3	4	4	2
Interest expense	21	19	17	16	18	23	21	20	22	105	16	20
Other non-operating income	−5	−4	−4	3	1	−2	−2	−2	−2	−75	−3	−2
Income before tax	29	47	37	29	16	17	3	17	43	29	19	−14
Income tax expense	8	15	9	9	6	5	1	5	12	12	4	2
Net income from continuing operations	21	32	28	20	9	13	2	12	32	17	14	−15
Net income	21	32	28	20	9	13	2	12	32	17	14	−15
EPS, basic	$0.61	$0.99	$0.86	$0.60	$0.33	$0.39	$0.08	$0.38	$1.00	$0.54	$0.45	−$0.46
EPS, diluted	$0.53	$0.82	$0.71	$0.52	$0.27	$0.35	$0.07	$0.34	$0.84	$0.46	$0.40	−$0.46
Weighted average shares, basic	34	32	32	32	32	32	32	32	32	32	32	32
Weighted average shares, diluted	42	41	41	40	40	40	33	39	39	40	40	32
EBITDA	87	101	89	80	76	96	80	94	122	304	91	71
Depreciation & amortization	37	35	35	35	42	57	57	57	57	170	56	65
EBIT	50	66	54	45	34	40	24	37	65	134	35	6